CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

Adjunctive Cilostazol to Dual Antiplatelet Therapy to Enhance Mobilization of Endothelial Progenitor Cell in Patients with Acute Myocardial Infarction: A Randomized, Placebo-Controlled EPISODE Trial Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study Osteoarthritis risk is reduced after treatment with ticagrelor compared to clopidogrel: a propensity score matching analysis Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial Infarction Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial

Guideline26 August 2017

JOURNAL:European Heart Journal Article Link

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery

M.Valgimigli, H. Bueno, R. A. Byrne et al Keywords: Myocardial DiseaseAcute Coronary Syndromes (ACS)Cardiovascular Pharmacology and Pharmacotherapy

Full Text PDF